The role of glutamate signaling in the pathogenesis and treatment of obsessive–compulsive disorder

• Published in: Pharmacology, biochemistry and behavior Vol. 100; no. 4; pp. 726 - 735
• Main Authors: Wu, Ke, Hanna, Gregory L., Rosenberg, David R., Arnold, Paul D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2012
• Subjects: Animals; Genetic association studies; Glutamate; Glutamates - metabolism; Humans; Knockout mouse models; Magnetic resonance spectroscopy; Mice; Mice, Transgenic; NMDA antagonists; Obsessive-Compulsive Disorder - drug therapy; Obsessive-Compulsive Disorder - metabolism; Riluzole; Signal Transduction; Magnetic resonance spectroscopy; Genetic association studies; NMDA antagonists; Knockout mouse models; Glutamate; Riluzole
• ISSN: 0091-3057; 1873-5177
• DOI: 10.1016/j.pbb.2011.10.007

Obsessive–compulsive disorder (OCD) is a common and often debilitating neuropsychiatric condition characterized by persistent intrusive thoughts (obsessions), repetitive ritualistic behaviors (compulsions) and excessive anxiety. While the neurobiology and etiology of OCD has not been fully elucidated, there is growing evidence that disrupted neurotransmission of glutamate within corticalstriatal–thalamocortical (CSTC) circuitry plays a role in OCD pathogenesis. This review summarizes the findings from neuroimaging, animal model, candidate gene and treatment studies in the context of glutamate signaling dysfunction in OCD. First, studies using magnetic resonance spectroscopy are reviewed demonstrating altered glutamate concentrations in the caudate and anterior cingulate cortex of patients with OCD. Second, knockout mouse models, particularly the DLGAP3 and Sltrk5 knockout mouse models, display remarkably similar phenotypes of compulsive grooming behavior associated with glutamate signaling dysfunction. Third, candidate gene studies have identified associations between variants in glutamate system genes and OCD, particularly for SLC1A1 which has been shown to be associated with OCD in five independent studies. This converging evidence for a role of glutamate in OCD has led to the development of novel treatment strategies involving glutamatergic compounds, particularly riluzole and memantine. We conclude the review by outlining a glutamate hypothesis for OCD, which we hope will inform further research into etiology and treatment for this severe neuropsychiatric condition. ► Reviews neuroimaging, genetic and animal model studies of OCD. ► Converging evidence suggests post-synaptic dysfunction in glutamate signaling. ► Glutamatergic modulating agents (e.g. riluzole and memantine) have shown efficacy.